Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Open Access
- 1 May 2007
- journal article
- review article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 117 (5), 1147-1154
- https://doi.org/10.1172/jci31178
Abstract
Tumors arise from normal cells of the body through genetic mutation. Although such genetic mutation often leads to the expression of abnormal antigens, the immune system fails to respond effectively to these antigens; that is, it is tolerant of these antigens. This acquired state of tolerance must be overcome for cancer immunotherapy to succeed. Indoleamine 2,3-dioxygenase (IDO) is one molecular mechanism that contributes to tumor-induced tolerance. IDO helps create a tolerogenic milieu in the tumor and the tumor-draining lymph nodes, both by direct suppression of T cells and enhancement of local Treg-mediated immunosuppression. It can also function as an antagonist to other activators of antitumor immunity. Therefore, strategies to block IDO might enhance the effectiveness of tumor immunotherapy.Keywords
This publication has 130 references indexed in Scilit:
- CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaquesBlood, 2006
- Indoleamine 2,3-dioxygenase–expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infectionJCI Insight, 2006
- Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancerBritish Journal of Cancer, 2006
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Tumour–induced immune modulation of sentinel lymph nodesNature Reviews Immunology, 2006
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006
- Coping with stress: eIF2 kinases and translational controlBiochemical Society Transactions, 2006
- Breaking down the barriers to cancer immunotherapyNature Immunology, 2005
- Complementary Role of CD4+ T Cells and Secondary Lymphoid Tissues for Cross-presentation of Tumor Antigen to CD8+ T CellsThe Journal of Experimental Medicine, 2003
- An Integrated Stress Response Regulates Amino Acid Metabolism and Resistance to Oxidative StressMolecular Cell, 2003